Advertisement
Original Article|Articles in Press

The ALDH2, IGSF9, and PRDM16 Proteins as Predictive Biomarkers for Prognosis in Breast Cancer

  • Author Footnotes
    $ Yunwei Han and Yiru Fu contributed equally to this work.
    Yunwei Han
    Footnotes
    $ Yunwei Han and Yiru Fu contributed equally to this work.
    Affiliations
    Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    National Clinical Research Center of Cancer, Tianjin, China

    Tianjin's Clinical Research Center for Cancer, Tianjin, China

    Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China

    Ministry of Education, Breast Cancer Innovation Team of the Ministry of Education, Tianjin, China

    Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Breast Cancer Research, Tianjin, China
    Search for articles by this author
  • Author Footnotes
    $ Yunwei Han and Yiru Fu contributed equally to this work.
    Yiru Fu
    Footnotes
    $ Yunwei Han and Yiru Fu contributed equally to this work.
    Affiliations
    Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    National Clinical Research Center of Cancer, Tianjin, China

    Tianjin's Clinical Research Center for Cancer, Tianjin, China

    Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China

    Ministry of Education, Breast Cancer Innovation Team of the Ministry of Education, Tianjin, China

    Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Breast Cancer Research, Tianjin, China
    Search for articles by this author
  • Qianqian Shi
    Affiliations
    Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    National Clinical Research Center of Cancer, Tianjin, China

    Tianjin's Clinical Research Center for Cancer, Tianjin, China

    Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China

    Ministry of Education, Breast Cancer Innovation Team of the Ministry of Education, Tianjin, China

    Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Breast Cancer Research, Tianjin, China

    Department of Laboratory Medicine, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
    Search for articles by this author
  • Hanjiao Liu
    Affiliations
    Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    National Clinical Research Center of Cancer, Tianjin, China

    Tianjin's Clinical Research Center for Cancer, Tianjin, China

    Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China

    Ministry of Education, Breast Cancer Innovation Team of the Ministry of Education, Tianjin, China

    Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Breast Cancer Research, Tianjin, China
    Search for articles by this author
  • Hui Sun
    Affiliations
    Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    National Clinical Research Center of Cancer, Tianjin, China

    Tianjin's Clinical Research Center for Cancer, Tianjin, China

    Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China

    Ministry of Education, Breast Cancer Innovation Team of the Ministry of Education, Tianjin, China

    Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Breast Cancer Research, Tianjin, China
    Search for articles by this author
  • Chen Niu
    Affiliations
    Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    National Clinical Research Center of Cancer, Tianjin, China

    Tianjin's Clinical Research Center for Cancer, Tianjin, China

    Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China

    Ministry of Education, Breast Cancer Innovation Team of the Ministry of Education, Tianjin, China

    Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Breast Cancer Research, Tianjin, China
    Search for articles by this author
  • Li Fu
    Correspondence
    Address for correspondence: Li Fu, Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
    Affiliations
    Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    National Clinical Research Center of Cancer, Tianjin, China

    Tianjin's Clinical Research Center for Cancer, Tianjin, China

    Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China

    Ministry of Education, Breast Cancer Innovation Team of the Ministry of Education, Tianjin, China

    Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Breast Cancer Research, Tianjin, China
    Search for articles by this author
  • Author Footnotes
    $ Yunwei Han and Yiru Fu contributed equally to this work.
Published:December 20, 2022DOI:https://doi.org/10.1016/j.clbc.2022.12.009

      Abstract

      Introduction

      ALDH2, IGSF9, and PRDM16 play crucial roles in regulating diverse cellular pathophysiologic functions. The current study was to evaluate the effect of the 3 proteins on clinicopathologic features and prognosis of patients with breast cancer.

      Materials and Methods

      The formalin-fixed and paraffin-embedded tissue specimens were collected from breast cancer patients by immunohistochemistry (IHC) were analyzed.

      Results

      Of the 216 patients enrolled, ALDH2 high expression was significantly correlated with the age (p = .040), larger tumor size (p = .001), LVI (p < .001), LNM (p < .001), advanced TNM staging (p < .001), PR (p = .027), HER2 status (p = .002), and molecular subtype (p = .003). IGSF9 low expression was significantly correlated with the LV1 (p = .024), LNM (p = .024), advanced TNM staging (p = .001). The low expression of PRDM16 was significantly correlated with age (p = .023), and LNM (p = .014). The A+IP expression (13.4%) were markedly correlated with lymphatic vessel invasion (LVI) (p < .001), lymph node metastasis (LNM) (p < .001), advanced TNM staging (p < .001). Furthermore, patients with A+IP expression had significantly advanced-stage breast cancer [stage III (72.4%) vs. (23.0%)]. Univariate and multivariate analysis identified variables (ie, larger tumor size, lymph node involvement, and A+IP expression) as independent prognostic factors for survival.

      Conclusion

      Our results reveal ALDH2 high expression, IGSF9 and PRDM16 low expression, A+IP expression was associated with advanced clinicopathological characteristics, and shorter OS and DFS in breast cancer patients. The 3 proteins may be potential prognosis markers and therapeutic targets for breast cancer patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bray F
        • Ferlay J
        • Soerjomataram I
        • Siegel RL
        • Torre LA
        • Jemal A
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68: 394-424
        • Hutchinson SA
        • Websdale A
        • Cioccoloni G
        • et al.
        Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer.
        Oncogene. 2021; 40: 2872-2883
        • Gwili N
        • Jones SJ
        • Amri WA
        • et al.
        Transcriptome profiles of stem-like cells from primary breast cancers allow identification of ITGA7 as a predictive marker of chemotherapy response.
        Br J Cancer. 2021; 125: 983-993
        • Fu L
        • Ikuo M
        • Fu XY
        • Liu TH
        • Shinichi T.
        [Relationship between biologic behavior and morphologic features of invasive micropapillary carcinoma of the breast].
        Zhonghua Bing Li Xue Za Zhi. 2004; 33: 21-25
        • Guo X
        • Chen L
        • Lang R
        • Fan Y
        • Zhang X
        • Fu L.
        Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis.
        Am J Clin Pathol. 2006; 126: 740-746
        • Chen L
        • Fan Y
        • Lang RG
        • Guo XJ
        • Sun YL
        • Cui LF
        • et al.
        Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases.
        Int J Surg Pathol. 2008; 16: 155-163
        • Shi Q
        • Shao K
        • Jia H
        • Cao B
        • Li W
        • Dong S
        • et al.
        Genomic alterations and evolution of cell clusters in metastatic invasive micropapillary carcinoma of the breast.
        Nat Commun. 2022; 13: 111
        • Hsu LC
        • Tani K
        • Fujiyoshi T
        • Kurachi K
        • Yoshida A
        Cloning of cDNAs for human aldehyde dehydrogenases 1 and 2.
        Proc Natl Acad Sci U S A. 1985; 82: 3771-3775
        • Hansen M
        • Walmod PS.
        IGSF9 family proteins.
        Neurochem Res. 2013; 38: 1236-1251
        • Nishikata I
        • Sasaki H
        • Iga M
        • et al.
        A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation.
        Blood. 2003; 102: 3323-3332
        • Chi J
        • Cohen P
        The multifaceted roles of PRDM16: adipose biology and beyond.
        Trends Endocrinol Metab. 2016; 27: 11-23
        • Zheng K
        • Yu J
        • Chen Z
        • et al.
        Ethanol promotes alcohol-related colorectal cancer metastasis via the TGF-β/RUNX3/Snail axis by inducing TGF-β1 upregulation and RUNX3 cytoplasmic mislocalization.
        EBioMedicine. 2019; 50: 224-237
        • Waris S
        • Patel A
        • Ali A
        • Mahmood R
        Acetaldehyde-induced oxidative modifications and morphological changes in isolated human erythrocytes: an in vitro study.
        Environ Sci Pollut Res Int. 2020; 27: 16268-16281
        • Moreb JS
        • Ucar D
        • Han S
        • et al.
        The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance.
        Chem Biol Interact. 2012; 195: 52-60
        • Ferreira-Teixeira M
        • Parada B
        • Rodrigues-Santos P
        • et al.
        Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors.
        Oncotarget. 2015; 6: 36185-36201
        • Hou G
        • Chen L
        • Liu G
        • et al.
        Aldehyde dehydrogenase-2 (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP-activated protein kinase signaling in mice.
        Hepatology. 2017; 65: 1628-1644
        • Chen L
        • Wu M
        • Ji C
        • Yuan M
        • Liu C
        • Yin Q
        Silencing transcription factor FOXM1 represses proliferation, migration, and invasion while inducing apoptosis of liver cancer stem cells by regulating the expression of ALDH2.
        IUBMB Life. 2020; 72: 285-295
        • Doudney K
        • Murdoch JN
        • Braybrook C
        • et al.
        Cloning and characterization of Igsf9 in mouse and human: a new member of the immunoglobulin superfamily expressed in the developing nervous system.
        Genomics. 2002; 79: 663-670
        • Ferguson K
        • Long H
        • Cameron S
        • Chang WT
        • Rao Y.
        The conserved Ig superfamily member Turtle mediates axonal tiling in Drosophila.
        J Neurosci. 2009; 29: 14151-14159
        • Mishra A
        • Traut MH
        • Becker L
        • Klopstock T
        • Stein V
        • Klein R.
        Genetic evidence for the adhesion protein IgSF9/Dasm1 to regulate inhibitory synapse development independent of its intracellular domain.
        J Neurosci. 2014; 34: 4187-4199
        • Fei LR
        • Huang WJ
        • Wang Y
        • et al.
        PRDM16 functions as a suppressor of lung adenocarcinoma metastasis.
        J Exp Clin Cancer Res. 2019; 38: 35
        • Dao FT
        • Chen WM
        • Long LY
        • et al.
        High PRDM16 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk: a comprehensive cohort study from a single Chinese center.
        Leuk Lymphoma. 2021; 62: 185-193
        • Lei Q
        • Liu X
        • Fu H
        • et al.
        miR-101 reverses hypomethylation of the PRDM16 promoter to disrupt mitochondrial function in astrocytoma cells.
        Oncotarget. 2016; 7: 5007-5022
        • Meng X
        • Zhao Y
        • Liu J
        • et al.
        Comprehensive analysis of histone modification-associated genes on differential gene expression and prognosis in gastric cancer.
        Exp Ther Med. 2019; 18: 2219-2230
        • Kundu A
        • Nam H
        • Shelar S
        • et al.
        PRDM16 suppresses HIF-targeted gene expression in kidney cancer.
        J Exp Med. 2020; 217
        • Tan SX
        • Hu RC
        • Liu JJ
        • Tan YL
        • Liu WE.
        Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells.
        Int J Clin Exp Pathol. 2014; 7: 2305-2311
        • Li Y
        • Chu J
        • Feng W
        • et al.
        EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
        FASEB J. 2019; 33: 4851-4865
        • Vigneswaran N
        • Wu J
        • Sacks P
        • Gilcrease M
        • Zacharias W
        Microarray gene expression profiling of cell lines from primary and metastatic tongue squamous cell carcinoma: possible insights from emerging technology.
        J Oral Pathol Med. 2005; 34: 77-86
        • Xu Y
        • Kajimoto S
        • Nakajo S
        • Nakaya K
        Beta-hydroxyisovalerylshikonin and cisplatin act synergistically to inhibit growth and to induce apoptosis of human lung cancer DMS114 cells via a tyrosine kinase-dependent pathway.
        Oncology. 2004; 66: 67-75
        • Xin M
        • Wang Y
        • Ren Q
        • Guo Y.
        Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro.
        Biomed Pharmacother. 2019; 109: 2084-2089
        • Zhang Y
        • Wang C
        • Zhou J
        • et al.
        Complex inhibition of autophagy by mitochondrial aldehyde dehydrogenase shortens lifespan and exacerbates cardiac aging.
        Biochim Biophys Acta Mol Basis Dis. 2017; 1863: 1919-1932
        • Zhang Y
        • Mi SL
        • Hu N
        • et al.
        Mitochondrial aldehyde dehydrogenase 2 accentuates aging-induced cardiac remodeling and contractile dysfunction: role of AMPK, Sirt1, and mitochondrial function.
        Free Radic Biol Med. 2014; 71: 208-220
        • Kissig M
        • Ishibashi J
        • Harms MJ
        • et al.
        PRDM16 represses the type I interferon response in adipocytes to promote mitochondrial and thermogenic programing.
        EMBO J. 2017; 36: 1528-1542